Cancer

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue SarcomaDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) --…

4 months ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their…

4 months ago

ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease

First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

4 months ago

Defence Therapeutics Announces Debenture Units Financing

Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…

4 months ago

Promotional Activity Engagements

VANCOUVER, BC / ACCESS Newswire / August 22, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) reports two…

4 months ago

Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the…

4 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a…

4 months ago

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent…

4 months ago

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design…

4 months ago

Prostadine Drops Reviews (Consumer Reports 2025) Is It Safe for Men? Shocking Truth About Results & Complaints

MIAMI, FL / ACCESS Newswire / August 21, 2025 / Constantly having the urge to pee or having trouble urinating…

4 months ago